Teva Pharmaceuticals' Phase 3 SOLARIS trial for TEV-749 long-acting schizophrenia injection shows significant improvements and no post-injection delirium/sedation syndrome.
Teva Pharmaceuticals announced positive results from its Phase 3 SOLARIS trial for TEV-749, a long-acting injection for schizophrenia. The study met its primary endpoint, showing significant improvements in the Positive and Negative Syndrome Scale (PANSS) and key secondary measures compared to placebo. Importantly, there were no cases of post-injection delirium/sedation syndrome, addressing a major concern with existing treatments. This could provide a new option for patients needing long-acting therapy.
September 21, 2024
6 Articles